VAX-31 Meets Phase 3 Goals, Putting Vaxcyte’s 31-Strain Pneumococcal Shot on a 2028 Filing Path

Vaxcyte shares surged after VAX-31 met adult Phase 3 goals versus Prevnar 20 and Capvaxive. A BLA filing is targeted for the first half of 2028.